6505--VISN IDIQ LENALIDOMIDE Sole Source Justification
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the VISN 02 Contracting Office, has issued a Special Notice indicating its intent to award a sole-source contract to Exelan Pharmaceuticals for the continuous supply of Lenalidomide. This action is not a request for quotes or an open solicitation, but a justification for a limited source acquisition valued at an estimated $26,272,218.00. The deadline for interested parties to submit comments regarding this sole-source justification is May 19, 2026.
Scope of Action
The VA requires a reliable and continuous supply of Lenalidomide, an immunomodulatory drug used to treat multiple myeloma, anemia in myelodysplastic syndromes (MDS), and certain types of lymphoma. The contractor will be responsible for providing Lenalidomide in various dosages (2.5MG, 5MG, 10MG, 15MG, 20MG, 25MG capsules) in accordance with all applicable federal regulations, Good Manufacturing Practices (cGMP), and Food and Drug Administration (FDA) requirements. This procurement addresses an emergent need to ensure continuous supply, meet regulatory obligations (Risk Evaluation and Mitigation Strategy – REMS program), and support patient access.
Contract Details
- Type: Sole-Source Contract (Notice of Intent)
- Proposed Contractor: Exelan Pharmaceuticals, Boca Raton, FL
- Estimated Value: $26,272,218.00
- Set-Aside: None specified (sole-source justification)
- Justification Rationale: The justification cites that the items are peculiar to one manufacturer (GSAR 538.7104-4), offer cost-effectiveness compared to brand-name alternatives, are on the VA National Formulary, and require dispensing by REMS-certified pharmacies. Market research identified an existing Federal Supply Schedule (FSS) contract (36F79720D0227) with Exelan Pharmaceuticals for this item.
Timeline & Contact
- Published Date: May 5, 2026
- Response Date (for comments on justification): May 19, 2026, 8:00 PM ET
- Primary Contact: Corey Swinton, Contract Specialist, Corey.Swinton@va.gov
Important Note for Industry
This notice serves as a justification for a limited source acquisition and is not a request for quotes or proposals. It informs the public of the VA's intent to award a sole-source contract to Exelan Pharmaceuticals. Bidders interested in supplying this medication should understand the existing contract and the VA's justification for limited sourcing, as this is not an open bidding opportunity.